Sanofi files Dupixent for severe asthma

US regulators have accepted for review Sanofi/Regeneron’s biologic Dupixent as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.

• Source: pharmatimes
• 969
• March 6, 2018